Last $12.89 USD
Change Today -0.06 / -0.46%
Volume 204.7K
VNDA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 4:30 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

Audit Committee* - vanda pharmaceuticals inc (VNDA)

Name (Connections)Board RelationshipsTitleKey Developments
Richard Dugan 13 RelationshipsDirector and Chairman of Audit Committee 
Vincent Milano 146 RelationshipsDirector, Chairman of Compensation Committee and Member of Audit Committee 
Michael Cola 60 RelationshipsDirector and Member of Audit Committee 

Compensation Committee* - vanda pharmaceuticals inc (VNDA)

Name (Connections)Board RelationshipsTitle
Vincent Milano 146 RelationshipsDirector, Chairman of Compensation Committee and Member of Audit Committee
Howard Pien 47 RelationshipsDirector, Member of Nominating/Corporate Governance Committee and Member of Compensation Committee
H. Watkins 121 RelationshipsChairman, Chairman of Nominating/Corporate Governance Committee and Member of Compensation Committee
VNDA Compensation vs. Industry
515.0K
362.8K
Chief Executive Officer
315.0K
268.0K
Chief Financial Officer
Share price activity for VANDA PHARMACEUTICALS INC (VNDA)
52 Week Price Performance
VNDA
Industry Average

Nominating Committee* - vanda pharmaceuticals inc (VNDA)

Name (Connections)Board RelationshipsTitleKey Developments
H. Watkins 121 RelationshipsChairman, Chairman of Nominating/Corporate Governance Committee and Member of Compensation CommitteeVanda Pharmaceuticals, Inc. Announces Termination of Robert Repella, Senior Vice President and Chief Commercial Officer, Effective as of January 1, 2014
12/4/13
Howard Pien 47 RelationshipsDirector, Member of Nominating/Corporate Governance Committee and Member of Compensation CommitteeVanda Pharmaceuticals, Inc. Appoints Paolo Baroldi as Senior Vice President and Chief Medical Officer
04/17/13
Steven Galson M.D., M.P.H 6 RelationshipsDirector and Member of Nominating/Corporate Governance CommitteeVanda Pharmaceuticals, Inc. Announces Board and Committee Changes
06/18/12

Corporate Governance Committee* - vanda pharmaceuticals inc (VNDA)

Name (Connections)Board RelationshipsTitle
Steven Galson M.D., M.P.H 6 RelationshipsDirector, Chairman of Compensation Committee and Member of Audit Committee
Howard Pien 47 RelationshipsDirector, Member of Nominating/Corporate Governance Committee and Member of Compensation Committee
H. Watkins 121 RelationshipsChairman, Chairman of Nominating/Corporate Governance Committee and Member of Compensation Committee
VNDA and Competitor
Insiders vs. External
Board
29%
71%
Vanda Pharmaceuticals, Inc.
13%
87%
Eli Lilly and Company
15%
85%
AstraZeneca PLC
17%
83%
Sanofi
38%
62%
Sumitomo Dainippon Pharma Co., Ltd.
13%
87%
Transcept Pharmaceuticals, Inc.
Insiders
External Board Members
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $12.89 USD -0.06

VNDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,449 GBp -18.50
Eli Lilly & Co $63.00 USD +0.19
Sanofi €83.39 EUR +0.45
Sumitomo Dainippon Pharma Co Ltd ¥1,413 JPY 0.00
Transcept Pharmaceuticals Inc $2.22 USD +0.05
View Industry Companies
 

Industry Analysis

VNDA

Industry Average

Valuation VNDA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.7x
Price/Book 495.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.